ACH vs MDWD
ACH: Accendra Health delivers home healthcare equipment and medical supplies through Apria and Byram Healthcare brands, though the company faces severe financial headwinds including 75% revenue decline, negative profitability, and substantial debt relative to market value. MDWD: MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision.
Side-by-side fundamentals
| Metric | ACH | MDWD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.22 | $14.45 | |
| Market cap as of 2026-07-30 | $247M | $188M | |
| PEG as of 2026-07-30 | -0.00 | -0.78 | MDWD lower |
| Net margin as of 2026-07-30 | -39.8% | -180.3% | ACH higher |
| Gross margin as of 2026-07-30 | +46.0% | +19.6% | ACH higher |
| Operating margin as of 2026-07-30 | +0.9% | -193.5% | ACH higher |
| ROE as of 2026-07-30 | -50.9% | -67.2% | ACH higher |
| ROA as of 2026-07-30 | -33.1% | -31.9% | MDWD higher |
| Debt / equity as of 2026-07-30 | 3.41 | 0.20 | MDWD lower |
| Revenue growth (YoY) as of 2026-07-30 | -74.7% | -24.6% | MDWD higher |
| Revenue CAGR (3y) SEC XBRL | -34.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 3 | n/a | |
| Beta as of 2026-07-30 | 1.60 | 0.14 | |
| 1-year return as of 2026-07-27 close | -59.1% | -28.9% | MDWD higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.